Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy

Study identifier:D5551R00012

ClinicalTrials.gov identifier:NCT02843399

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Clinical and Economic Outcomes of Patients with Type 2 Diabetes Mellitus initiating Bydureon and Glargine

Medical condition

Diabetes mellitus type 2

Phase

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

15498

Study type

Observational

Age

18 Years - 99 Years

Date

Study Start Date: 15 Aug 2016

Primary Completion Date: 15 Dec 2016

Study Completion Date: 15 Dec 2016

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Dec 2017 by AstraZeneca

Collaborators

Truven Health

Inclusion and exclusion criteria

Location

Research site

Wilmington, DE, United States

Arms	Assigned Interventions
Exenatide once weekly (EQW) EQW cohort includes patients with one or more outpatient prescription claims for EQW between 2012 and 2015.	-
Insulin Glargine (IG) IG cohort includes patients with one or more outpatient prescription claims for IG between 2012 and 2015	-

"There is no result for the study"

Documents available

Synopsis_D5551R00012
Download
Trial Results Summaries
Available here

Contacts

Contact

Eric Wittbrodt

856-220-6433

Eric.Wittbrodt@astrazeneca.com

Contact Backup

Amanda Farr

203-691-9200

amanda.farr@truvenhealth.com

Investigators

Principal Investigator

Eric T. Wittbrodt

AstraZeneca